New Delhi, Feb. 13 -- NATCO Pharma Ltd reported a sharp decline of 37.75 percent in consolidated net profit for the December quarter, primarily impacted by a downturn in formulations exports. The company's consolidated net profit stood at Rs.132.4 crore in Q3 FY2025, a drop from Rs.212.7 crore recorded in the corresponding quarter of the previous fiscal year, according to a regulatory filing.

The pharmaceutical firm's consolidated revenue from operations fell to Rs.474.8 crore in Q3 FY2025, down from Rs.758.6 crore in the year-ago period, reflecting a 37.4 percent decrease in earnings.

The company's earnings before interest, taxes, depreciation, and amortization (EBITDA) saw a drastic decline of 85.5 percent year-over-year, falling to R...